Table 3.

Incidence of serious infections among biologic users with PsO or PsA, overall and by drug class

	All biologic classes	IL-17	IL-12/23	TNF
Total cohort
Number of treatment episodes	11 560	2148	2882	6530
Total person-years of follow-up	9264	1528	2461	5275
Incident serious infections, n (%)	190 (2)	32 (1)	32 (1)	126 (2)
Incidence rate (95% CI), per 100 person-years	2.1 (1.8 to 2.4)	2.1 (1.5 to 2.9)	1.3 (0.9 to 1.8)	2.4 (2.0 to 2.8)
PsO
Number of treatment episodes	9691	1903	2644	5144
Total person-years of follow-up	8010	1406	2311	4293
Incident serious infections, n (%)	156 (2)	26 (1)	29 (1)	101 (2)
Incidence rate (95% CI), per 100 person-years	2.0 (1.7 to 2.3)	1.9 (1.2 to2.7)	1.3 (0.9 to 1.8)	2.4 (1.9 to 2.8)
PsA
Number of treatment episodes	5517	944	888	3685
Total person-years of follow-up	4159	605	647	2907
Incident serious infections, n (%)	105 (2)	14 (1)	13 (1)	78 (2)
Incidence rate (95% CI), per 100 person-years	2.5 (2.1 to 3.1)	2.3 (1.3 to 3.7)	2.0 (1.1 to 3.3)	2.7 (2.1 to 3.3)
Biologic-naïve
Number of treatment episodes	5995	332	1344	4319
Total person-years of follow-up	5019	237	1217	3565
Incident serious infections, n (%)	*	*	11 (1)	80 (2)
Incidence rate (95% CI), per 100 person-years	2.0 (1.6 to 2.4)	3.4 (1.6 to 6.3)	0.9 (0.5 to 1.6)	2.2 (1.8 to 2.8)
Biologic experienced
Number of treatment episodes	5565	1816	1538	2211
Total person-years of follow-up	4.246	1292	1244	1710
Incident serious infections, n (%)	91 (2)	24 (1)	21 (1)	46 (2)
Incidence rate (95% CI), per 100 person-years	2.1 (1.7 to 2.6)	1.9 (1.2 to 2.7)	1.7 (1.1 to 2.5)	2.7 (2.0 to 3.5)

^*Clinical description of cells with 10 or fewer observations suppressed per data license. IL, interleukin; TNF, tumour necrosis factor.